Eiger BioPharmaceuticals. has filed a patent for a method of treating a coronavirus infection in humans. The method involves subcutaneously administering pegylated interferon lambda-1a until a sustained reduction in viral load, undetectable levels of coronavirus RNA, decreased viral shedding, or improvement in symptoms is achieved. GlobalData’s report on Eiger BioPharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eiger BioPharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eiger BioPharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Eiger BioPharmaceuticals's grant share as of September 2023 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Method of treating coronavirus infection with pegylated interferon lambda-1a

Source: United States Patent and Trademark Office (USPTO). Credit: Eiger BioPharmaceuticals Inc

A recently filed patent (Publication Number: US20230285510A1) describes a method for treating coronavirus infections using pegylated interferon lambda-1a. The method involves subcutaneously administering the interferon to the subject until certain conditions are met, such as a sustained reduction in viral load, a decrease in viral shedding, or an improvement in symptoms. The interferon can be administered for various durations and at different doses, ranging from once a week to twice per week. The method can also involve administering other antiviral medications, such as remdesivir or chloroquine.

The patent claims that the treatment results in a reduction of coronavirus viral load and an improvement in the subject's symptoms. The symptoms that may improve include fever, fatigue, cough, shortness of breath, aches and pains, and diarrhea. The method can be used during the early phase of the coronavirus infection to shorten its duration and prevent respiratory complications. The subject can be a mild, non-hospitalized individual, a mild to moderate hospitalized individual, or an exposed individual with no symptoms.

The patent also describes methods for preventing or reducing the incidence of SARS-CoV-2 infection. This involves administering interferon lambda to the subject, either as a subcutaneous injection or through other routes, such as intravenous or intramuscular. The interferon can be administered at different doses and frequencies, and the subject's viral load and viral shedding can be monitored to assess the effectiveness of the treatment.

Overall, the patent claims to provide a method for treating and preventing coronavirus infections using pegylated interferon lambda-1a. The method aims to reduce viral load, improve symptoms, and prevent respiratory complications. The treatment can be tailored to different disease severities and can be combined with other antiviral medications. Further research and clinical trials may be needed to validate the effectiveness of this method.

To know more about GlobalData’s detailed insights on Eiger BioPharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies